Joint research on a regenerative medicine product for central nervous system diseases using iPS cell-derived neural glial cells
First written in FY2018-Q3. 17 of 25 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「Based on these promising nonclinical data, we will accelerate preparations for the early launch of clinical trials for ALS.」
In light of the significant suppression of motor function decline, long-term engraftment and motor neuron activation observed in ALS model rats treated with iPS-derived neural glial cells, the company has reaffirmed its policy of proceeding with preparations to launch clinical trials. - FY2026-H1AdvancedAnnual report
「It was also confirmed that the administered iPS-derived neural glial cells engrafted in the rats for an extended period and activated motor neurons.」
For iPS-derived neural glial cells, in addition to the significant suppression of motor function decline in ALS model rats, long-term engraftment and motor neuron activation were confirmed. The company stated that it would accelerate preparations for the launch of clinical trials based on the preclinical data. - FY2025AdvancedAnnual report
「In an experiment using an ALS model rat, a rat reproducing the pathology of ALS, motor function decline was significantly suppressed in the group administered iPS-derived neural glial cells compared with the non-administered group.」
For iPS-derived neural glial cells, a significant suppression of motor function decline in ALS model rats was reported, indicating progress from preclinical testing toward preparations for clinical trials. - FY2025-H1RestatedAnnual report
「We are currently conducting preclinical testing, including animal studies, using iPS-derived neural glial cells.」
For iPS-derived neural glial cells, the policy of continuing preclinical testing and using AMED’s support to aim for an early start to clinical trials has been reaffirmed. - FY2024-Q3RestatedAnnual report
「In October 2022, we were selected for AMED’s open call programme, the “Fundamental Technology Development Project for the Industrialisation of Regenerative Medicine and Gene Therapy.” With support from this programme, we aim to accelerate research and development and begin clinical trials as soon as possible.」
For iPS-derived neural glial cells, the policy of using AMED’s support to accelerate research and development and aim to begin clinical trials has been reaffirmed. - FY2024-Q2RestatedAnnual report
「In October 2022, we were selected for AMED’s open call programme, the “Fundamental Technology Development Project for the Industrialisation of Regenerative Medicine and Gene Therapy.” With support from this programme, we aim to accelerate research and development and begin clinical trials as soon as possible.」
For iPS-derived neural glial cells, the policy of using AMED’s support to accelerate research and development and aim to begin clinical trials has been reaffirmed. - FY2024-Q1RestatedAnnual report
「In October 2022, we were selected for AMED’s open call programme, the “Fundamental Technology Development Project for the Industrialisation of Regenerative Medicine and Gene Therapy.” With support from this programme, we aim to accelerate research and development and begin clinical trials as soon as possible.」
For iPS-derived neural glial cells, the policy of using AMED’s support to advance from preclinical testing and manufacturing capabilities to the launch of clinical trials has been reaffirmed. - FY2023-Q3AdvancedAnnual report
「In October 2022, we were selected for AMED’s open call programme, the “Fundamental Technology Development Project for the Industrialisation of Regenerative Medicine and Gene Therapy.” With support from this programme, we aim to accelerate research and development and begin clinical trials as soon as possible.」
For iPS-derived neural glial cells, we were selected for an AMED open call programme and obtained public support to accelerate research and development and aim to begin clinical trials. - FY2023-Q2RestatedAnnual report
「We are currently conducting preclinical testing, including animal studies, using iPS-derived neural glial cells with the Central Institute for Experimental Animals. We are also proceeding with preparations at the Tonamachi–ReproCELL Regenerative Medicine Center, located within the Kanagawa Life Innovation Center, for manufacturing iPS-derived neural glial cells, and obtained a licence to manufacture specified processed cells (facility number: FA3200006) from the Kanto-Shinetsu Regional Bureau of Health and Welfare of the Ministry of Health, Labour and Welfare in March 2021 under the Act on the Safety of Regenerative Medicine.」
For iPS-derived neural glial cells, preclinical testing and use of the Tonomachi Center, which has obtained a licence to manufacture specified processed cells, are continuing. - FY2023-Q1RestatedAnnual report
「We are currently conducting preclinical testing, including animal studies, using iPS-derived neural glial cells with the Central Institute for Experimental Animals. We are also proceeding with preparations at the Tonamachi–ReproCELL Regenerative Medicine Center, located within the Kanagawa Life Innovation Center, for manufacturing iPS-derived neural glial cells, and obtained a licence to manufacture specified processed cells (facility number: FA3200006) from the Kanto-Shinetsu Regional Bureau of Health and Welfare of the Ministry of Health, Labour and Welfare in March 2021 under the Act on the Safety of Regenerative Medicine.」
For iPS-derived neural glial cells, preclinical testing and the development and use of the Tonomachi Center, which has obtained a licence to manufacture specified processed cells, are continuing. - FY2022-Q3RestatedAnnual report
「We are currently conducting preclinical testing, including animal studies, using iPS-derived neural glial cells with the Central Institute for Experimental Animals. We are also proceeding with preparations at the Tonamachi–ReproCELL Regenerative Medicine Center, located within the Kanagawa Life Innovation Center, for manufacturing iPS-derived neural glial cells, and obtained a licence to manufacture specified processed cells (facility number: FA3200006) from the Kanto-Shinetsu Regional Bureau of Health and Welfare of the Ministry of Health, Labour and Welfare in March 2021 under the Act on the Safety of Regenerative Medicine.」
For iPS-derived neural glial cells, preclinical testing and the development and use of the Tonomachi Center, which has obtained a licence to manufacture specified processed cells, are continuing. - FY2022-Q1RestatedAnnual report
「We are currently conducting preclinical testing, including animal studies, using iPS-derived neural glial cells with the Central Institute for Experimental Animals. We are also proceeding with preparations at the Tonamachi–ReproCELL Regenerative Medicine Center, located within the Kanagawa Life Innovation Center, for manufacturing iPS-derived neural glial cells, and obtained a licence to manufacture specified processed cells (facility number: FA3200006) from the Kanto-Shinetsu Regional Bureau of Health and Welfare of the Ministry of Health, Labour and Welfare in March 2021 under the Act on the Safety of Regenerative Medicine.」
For iPS-derived neural glial cells, preclinical testing and use of the manufacturing facility licensed to manufacture specified processed cells are continuing. - FY2021AdvancedAnnual report
「During the current fiscal year, we conducted preclinical testing using iPS-derived neural glial cells, including animal studies, with the Central Institute for Experimental Animals. We also proceeded with preparations at the Tonamachi–ReproCELL Regenerative Medicine Center for manufacturing iPS-derived neural glial cells and obtained a licence to manufacture specified processed cells (facility number: FA3200006) from the Kanto-Shinetsu Regional Bureau of Health and Welfare of the Ministry of Health, Labour and Welfare in March 2021 under the Act on the Safety of Regenerative Medicine.」
For iPS-derived neural glial cells, preclinical testing was conducted and a licence to manufacture specified processed cells at the manufacturing facility was obtained in March 2021. - FY2021-Q3RestatedAnnual report
「In May 2019, we opened the Tonamachi–ReproCELL Regenerative Medicine Center for cell processing for regenerative medicine within the Life Innovation Center (LIC), established by Kanagawa Prefecture in the Tonomachi district of Kawasaki, and are currently preparing to manufacture products for clinical trials involving iPS-derived neural glial cells.」
Preparations for manufacturing products for clinical trials using the Tonamachi–ReproCELL Regenerative Medicine Center are continuing for the development of iPS-derived neural glial cells. - FY2021-Q2RestatedAnnual report
「In May 2019, we opened the Tonamachi–ReproCELL Regenerative Medicine Center for cell processing for regenerative medicine within the Life Innovation Center (LIC), established by Kanagawa Prefecture in the Tonomachi district of Kawasaki, and are currently preparing to manufacture products for clinical trials involving iPS-derived neural glial cells.」
Preparations for manufacturing products for clinical trials using the Tonamachi–ReproCELL Regenerative Medicine Center are continuing for the development of iPS-derived neural glial cells. - FY2021-Q1RestatedAnnual report
「In May 2019, we opened the Tonamachi–ReproCELL Regenerative Medicine Center for cell processing for regenerative medicine within the Life Innovation Center (LIC), established by Kanagawa Prefecture in the Tonomachi district of Kawasaki, and are currently preparing to manufacture products for clinical trials involving iPS-derived neural glial cells.」
Preparations for manufacturing products for clinical trials using the Tonamachi–ReproCELL Regenerative Medicine Center are continuing for the development of iPS-derived neural glial cells. - FY2020RestatedAnnual report
「In May 2019, we opened the Tonamachi–ReproCELL Regenerative Medicine Center for cell processing for regenerative medicine within the Life Innovation Center (LIC), established by Kanagawa Prefecture in the Tonomachi district of Kawasaki, and are currently preparing to manufacture products for clinical trials involving iPS-derived neural glial cells.」
Development of iPS-derived neural glial cells with MAGiQ Therapeutics and preparations for manufacturing products for clinical trials at the Tonomachi Center are continuing. - FY2020-Q3RestatedAnnual report
「To accelerate research and development for this project, we opened the Shonan Research Center at Shonan Health Innovation Park in December 2018. In May 2019, we also opened the Tonamachi–ReproCELL Regenerative Medicine Center for cell processing for regenerative medicine within the Life Innovation Center (LIC), established by Kanagawa Prefecture in the Tonomachi district of Kawasaki. We will use these new facilities to advance preclinical testing of iPS cell-derived neural glial cells and the manufacture of products for clinical trials.」
The plan to use the Shonan Research Center and the Tonamachi–ReproCELL Regenerative Medicine Center to advance preclinical testing of iPS cell-derived neural glial cells and manufacture products for clinical trials has been reaffirmed. - FY2020-Q2RestatedAnnual report
「To accelerate research and development for this project, we opened the Shonan Research Center at Shonan Health Innovation Park in December 2018. In May 2019, we also opened the Tonamachi–ReproCELL Regenerative Medicine Center for cell processing for regenerative medicine within the Life Innovation Center (LIC), established by Kanagawa Prefecture in the Tonomachi district of Kawasaki. We will use these new facilities to advance preclinical testing of iPS cell-derived neural glial cells and the manufacture of products for clinical trials.」
The plan to use the Shonan Research Center and the Tonamachi–ReproCELL Regenerative Medicine Center to advance preclinical testing of iPS cell-derived neural glial cells and manufacture products for clinical trials has been reaffirmed. - FY2020-Q1AdvancedAnnual report
「To accelerate research and development for this project, we opened the Shonan Research Center at Shonan Health Innovation Park in December 2018. In May 2019, we also opened the Tonamachi–ReproCELL Regenerative Medicine Center for cell processing for regenerative medicine within the Life Innovation Center (LIC), established by Kanagawa Prefecture in the Tonomachi district of Kawasaki. We will use these new facilities to advance preclinical testing of iPS cell-derived neural glial cells and the manufacture of products for clinical trials.」
For development of iPS cell-derived neural glial cells, the Shonan Research Center and the Tonamachi–ReproCELL Regenerative Medicine Center were opened, establishing the facilities needed for preclinical testing and the manufacture of products for clinical trials. - FY2019-Q3RaisedAnnual report
「The project initially focused on transverse myelitis and amyotrophic lateral sclerosis (ALS), but we aim to expand its application in the future to other central nervous system diseases, including spinal cord injury, multiple sclerosis, and Parkinson’s disease.」
The policy of expanding the indications for the iPS cell-derived neural glial cell product from the initial targets of transverse myelitis and ALS to spinal cord injury, multiple sclerosis, Parkinson’s disease, and other conditions was stated, broadening the scope of target diseases. - FY2019-Q2RestatedAnnual report
「To accelerate this project, we established the joint venture MAGiQ Therapeutics Co., Ltd. with US-based Q Therapeutics Inc. in April 2018. Q Therapeutics is a venture company specialising in regenerative medicine for the central nervous system. Combining its expertise with our iPS cell technology will accelerate development of iPS cell-derived neural glial cells.」
The framework of accelerating development of iPS cell-derived neural glial cells through the joint venture MAGiQ Therapeutics with Q Therapeutics has been reaffirmed. - FY2019-Q1RestatedAnnual report
「During the first quarter of the current consolidated fiscal year, we established the joint venture MAGiQ Therapeutics Co., Ltd. with US-based Q Therapeutics to accelerate development of iPS cell-derived neural glial cells (iGRP), a regenerative medicine product.」
The framework of advancing preclinical trials, clinical development, and out-licensing of iGRP through the joint venture with Q Therapeutics has been reaffirmed. - FY2018AdvancedAnnual report
「Under this agreement, we aim to commercialise regenerative medicine products effective against various central nervous system diseases using our proprietary iPS cell technology and promote medium- to long-term business growth.」
The joint research with Q Therapeutics progressed to the establishment of the joint venture MAGiQ Therapeutics, preclinical and clinical development of iGRP, and the acquisition of exclusive development and manufacturing licences in Japan for ALS and transverse myelitis. - FY2018-Q3First statedAnnual report
「During the first 3 quarters of the current consolidated fiscal year, we reached a basic agreement with US-based Q Therapeutics Inc. and its co-founder Dr Mahendra Rao on joint research into iPS cell-derived regenerative medicine products and launched the project. The purpose of this joint research is to produce neural glial cells (GRP) from iPS cells through directed differentiation and develop them as regenerative medicine products for central nervous system diseases such as amyotrophic lateral sclerosis (ALS) and transverse myelitis (TM).」
Based on the basic agreement with Q Therapeutics and Dr Mahendra Rao, a project was launched to develop iPS cell-derived neural glial cells as regenerative medicine products for central nervous system diseases such as ALS and transverse myelitis.